Note: Ingredients listed on restricted chemical lists
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
80 - 100
General Information
Version
1.0
Revision date
2025-04-14
Product name
Esmolol HCl in Water for Injection
1.2.1 Relevant identified uses
Pharmaceutical product indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in peri operative, postoperative or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. It is also indicated in non-compensatory sinus tachycardia where the rapid heart rate requires specific intervention
1.2.2. Uses advised against
No additional information available
Emergency telephone
+1-866-562-4708
Icons in SDS
Company Information
company name
WG Critical Care, LLC
e-mail address of the competent person responsible for the Safety Data Sheet
wgccquality@wgcriticalcare.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H373
Hazard statements
Code
Statements
H373
May cause damage to organs through prolonged or repeated exposure
Section 2
SECTION 2: Hazards identification
Classification of the Substance or Mixture GHS-US Classification Specific target organ toxicity — Repeated exposure, Category 2 H373
2.2 Label elements
GHS-US Labeling
Hazard pictograms
GHS08
Signal word
Warning
Hazard statements
H373 - May cause damage to organs (cardiovascular system) through prolonged or repeated exposure (oral, inhalation).
Precautionary statements
P260 - Do not breathe mist, spray, vapors. P314 - Get medical advice or attention if you feel unwell. P501 - Dispose of contents and/or container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulations. 2.3 Hazards associated with known or reasonably anticipated uses This product is a pharmaceutical product designed for administration to a patient by a qualified medical professional. No other uses are anticipated. A Process Hazard Analysis (PHA) or other hazard assessment for additional specific end uses should be performed to ensure that hazards are fully understood, and adequate safety measures are in place. See Section 10 for relevant reactivity and stability information.
2.3 Other hazards
Exposure may aggravate pre-existing eye, skin, or respiratory conditions.
Ingredient(s) with unknown acute toxicity
2% of the mixture consists of ingredient(s) of unknown acute toxicity (Oral, Dermal, Inhalation (Dust/Mist))
2.1 Classification of the substance or mixture
GHS-US Classification Specific target organ toxicity — Repeated exposure, Category 2 H373
